<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The prevalence of <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> and the risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> are elevated in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>This analysis compared the effects of insulin glargine versus <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> (TZDs) on <z:chebi fb="23" ids="18059">lipid</z:chebi> profiles </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Patient-level data were pooled from two randomized clinical studies </plain></SENT>
<SENT sid="3" pm="."><plain>The population included 552 men and women aged &gt;18 years, diagnosed with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> for at least 6 months, on <z:chebi fb="0" ids="6801">metformin</z:chebi> and/or sulphonylurea, and with A(1C) â‰¥7.5% and &lt;12.0% at screening </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="23" ids="18059">Lipid</z:chebi> outcome measures included change from baseline in <z:chebi fb="23" ids="18059">lipid</z:chebi> levels [<z:chebi fb="1" ids="47774">low-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47774">LDL-C</z:chebi>), <z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47775">HDL-C</z:chebi>), non-<z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi> (non-<z:chebi fb="0" ids="47775">HDL-C</z:chebi>), total cholesterol, <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, and free fatty acids] and attainment of <z:chebi fb="23" ids="18059">lipid</z:chebi> goals for <z:chebi fb="0" ids="47774">LDL-C</z:chebi>, non-<z:chebi fb="0" ids="47775">HDL-C</z:chebi>, and <z:chebi fb="4" ids="17855">triglycerides</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Both insulin glargine and TZDs improved <z:chebi fb="23" ids="18059">lipid</z:chebi> profiles from baseline values </plain></SENT>
<SENT sid="6" pm="."><plain>Compared with TZDs, treatment with insulin glargine led to 7.9% greater reduction in <z:chebi fb="0" ids="47774">LDL-C</z:chebi> (p &lt; 0.0003), 7.5% greater reduction in non-<z:chebi fb="0" ids="47775">HDL-C</z:chebi> (p &lt; 0.0001), and 7.8% greater reduction in total cholesterol (p &lt; 0.0001), whereas the <z:chebi fb="0" ids="47775">HDL-C</z:chebi> increase with TZD was 7.6% greater than that with insulin glargine (p &lt; 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>The percentage of patients attaining the <z:chebi fb="23" ids="18059">lipid</z:chebi> goals was comparable between insulin glargine and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, but lower for <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Insulin glargine improved glycaemic control more than TZDs; however, insulin glargine caused more <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment with TZDs caused more <z:mp ids='MP_0005456'>weight gain</z:mp> and peripheral <z:hpo ids='HP_0000969'>oedema</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: These findings suggest that the favourable effects of insulin glargine on plasma <z:chebi fb="23" ids="18059">lipid</z:chebi> profiles should be considered among the advantages of treatment with insulin glargine as they are for TZDs </plain></SENT>
</text></document>